Access
This article is part of Nature's premium content.
Published online 4 November 2008 | Nature | doi:10.1038/456006a
News
Industry shifts focus to immunology and cancer
Cardiology and anaemia lose out in the hunt for the next pharmaceutical blockbusters.
When Wyeth Pharmaceuticals announced last week that it would cut some of its research and development (R&D) programmes in women's health, the decision seemed counterintuitive. The pharmaceutical giant, based in New Jersey, is known for its strong work in contraceptives and hormone-replacement therapy.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
